Indeed, in preclinical GBM models, targeted MDM reprogramming by IL-6 inhibition with CD40 stimulation [114], SLIT2 inhibition, and monoacylglycerol lipase inhibition showed strong synergistic effects with ICIs such as anti-PD-1, anti-CTLA4, and anti-4-1BB. This evidence concerns the gene PDCD1 and glioblastoma.